Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Cerus Corporation

CERS
Current price
1.67 USD +0.02 USD (+1.21%)
Last closed 1.61 USD
Sector Healthcare
Industry Medical Devices
Exchange NASDAQ
Capitalization 298 975 040 USD
Yield for 12 month -59.76 %
Week
Month
Year
CERS
21.11.2021 - 28.11.2021

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California. Address: 1220 Concord Avenue, Concord, CA, United States, 94520

Analytics

WallStreet Target Price

4.13 USD

P/E ratio

Dividend Yield

Current Year

+162 048 000 USD

Last Year

+130 859 000 USD

Current Quarter

+39 772 000 USD

Last Quarter

+38 853 000 USD

Current Year

+87 094 000 USD

Last Year

+67 384 000 USD

Current Quarter

+21 816 000 USD

Last Quarter

+21 338 000 USD

Key Figures CERS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -34 651 000 USD
Operating Margin TTM -9.16 %
PE Ratio
Return On Assets TTM -11.05 %
PEG Ratio
Return On Equity TTM -81.05 %
Wall Street Target Price 4.13 USD
Revenue TTM 153 632 992 USD
Book Value 0.27 USD
Revenue Per Share TTM 0.86 USD
Dividend Share
Quarterly Revenue Growth YOY 0.5 %
Dividend Yield
Gross Profit TTM 87 094 000 USD
Earnings Share -0.27 USD
Diluted Eps TTM -0.27 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin -32.4 %

Dividend Analytics CERS

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CERS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation CERS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 4.324
Price Sales TTM 4.7423
Enterprise Value EBITDA -23.2088
Price Book MRQ 9.5602

Financials CERS

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators CERS

For 52 weeks

1.21 USD 4.25 USD
50 Day MA 1.5 USD
Shares Short Prior Month 5 594 565
200 Day MA 2.2 USD
Short Ratio 6.5
Shares Short 6 237 448
Short Percent 3.55 %